Medications, substances, and lifestyle factors that quietly kill your testosterone

Yes. Opioids, anabolic steroids, heavy alcohol use, obesity, and chronic sleep loss can all lower testosterone enough to produce male hypogonadism, which Veedma evaluates when total testosterone is below 350 ng/dL or free testosterone is below 100 pg/mL in men with persistent symptoms. This matters because many medications that lower testosterone do not damage the testes directly. They suppress the brain to testes signaling loop, which means the right treatment depends on LH and FSH, not on testosterone alone.

Key takeaways

• Male hypogonadism is a clinical syndrome that requires both persistent symptoms and biochemical evidence of testosterone deficiency. One low lab value alone is not a diagnosis.
• Veedma uses a total testosterone threshold of 350 ng/dL and a free testosterone threshold of 100 pg/mL when symptoms persist, with testing done in the morning from 07:00 to 11:00 in the fasting state.
• LH and FSH must be measured with testosterone every time. High LH with low testosterone points to primary hypogonadism, while low or normal LH with low testosterone points to secondary hypogonadism.
• Opioids are among the strongest drugs that cause low testosterone because they suppress GnRH, LH, and FSH. Exogenous testosterone and anabolic steroids strongly suppress natural testosterone production through negative feedback and can lead to secondary hypogonadism, especially after discontinuation or when endogenous production is being assessed.
• Obesity is the single most evidence backed modifiable cause of low testosterone, largely through increased aromatase activity in fat tissue that raises estradiol and suppresses the HPG axis.
• Chronic heavy alcohol use and chronic systemic disease can produce mixed hypogonadism. Chemotherapy, especially alkylating agents, more often causes primary hypogonadism through direct testicular damage. Some endocrine disrupting chemicals may also impair testicular function, although individual causation is hard to prove in adults.

When these factors actually count as hypogonadism

Male hypogonadism is a clinical syndrome that requires both persistent symptoms and confirmed biochemical testosterone deficiency on reliable morning testing.^[1]

Biochemical evidence means consistently low testosterone on a properly collected blood test. Symptoms matter just as much. In practice, that usually means sexual symptoms such as low libido, erectile dysfunction, or loss of morning erections, often with fatigue, reduced physical performance, or worsening body composition. For the diagnostic standard itself, see the clinical definition of low testosterone.

According to the Endocrine Society guideline, testosterone should be measured in the morning and confirmed on repeat testing, and it should not be diagnosed during acute illness because illness can cause temporary suppression.^[1] At Veedma, blood is drawn from 07:00 to 11:00 in the fasting state. We prioritize free testosterone because hidden testosterone deficiency can be missed when total testosterone looks acceptable. We measure free testosterone directly by equilibrium dialysis with LC MS/MS, not by immunoassay and not by SHBG based calculation. When symptoms persist, Veedma uses 350 ng/dL for total testosterone and 100 pg/mL for free testosterone as decision thresholds.

LH and FSH are the decisive companion tests because they classify where the problem starts.^[2] The HPG axis is the hormone signaling loop between the hypothalamus, pituitary, and testes. Primary hypogonadism means the testes are failing. Secondary hypogonadism means the brain is not sending enough LH and FSH. High LH with low testosterone points to primary disease. Low or normal LH with low testosterone points to secondary disease. That distinction determines whether a man needs testosterone replacement or is a candidate for Enclomiphene. For the full reasoning, see primary vs secondary hypogonadism.

This is why Veedma does not guess from a testosterone number alone. Our men’s health panel includes total testosterone, free testosterone by equilibrium dialysis plus LC MS/MS, estradiol, LH, FSH, CBC with hematocrit, comprehensive metabolic panel, and PSA for men 40 and older. When indicated, prolactin, thyroid testing, vitamin D, and a lipid panel are added. Veedma can order this 40 plus biomarker workup twice yearly or review existing outside labs, including Function Health results, to determine whether medications that lower testosterone, substances that lower testosterone, or lifestyle causes of low testosterone are actually producing a treatable syndrome.

Opioids, exogenous testosterone, and anabolic steroids

Opioids and exogenous androgens are among the strongest medication causes of acquired secondary hypogonadism because they suppress hypothalamic and pituitary signaling to the testes.^{[3] [4]}

Opioids and testosterone

The relationship between opioids and testosterone is one of the clearest examples of drug induced secondary hypogonadism. Opioids suppress GnRH secretion, which lowers LH and FSH and then lowers testicular testosterone production.^[3] GnRH is the hypothalamic signal that tells the pituitary to release LH and FSH. When that upstream signal is blunted, the testes may be structurally intact but under stimulated.

This pattern usually shows up as low or inappropriately normal LH and FSH with low testosterone, not as high LH from testicular failure. That matters clinically. If a man on chronic opioids has persistent symptoms and confirmed low testosterone, this is usually a central suppression problem rather than permanent testicular damage. Because the mechanism is central, Enclomiphene is a logical treatment option when LH is below 8 mIU/mL. It blocks estrogen receptors at the hypothalamus, increases GnRH and LH output, and can help restore natural testosterone production while preserving fertility and testicular function.^[14]

Opioid induced suppression can improve after dose reduction or discontinuation, but recovery is not always immediate. Some men remain symptomatic for months and still need formal evaluation. In a real world setting of long term pain treatment and high opioid prescribing, this is one of the most important drugs that cause low testosterone to look for before deciding on therapy.

Exogenous testosterone and anabolic steroids

The irony is that testosterone itself can be one of the drugs that cause low testosterone after it is stopped. Exogenous testosterone and anabolic steroids raise circulating androgen levels, which increases negative feedback to the hypothalamus and pituitary. The result is suppression of LH and FSH, reduced intratesticular testosterone, and impaired natural production.^{[4] [5]}

Exogenous testosterone suppresses gonadotropins and intratesticular testosterone, which is one reason spermatogenesis falls on treatment.^[4] In other words, a man using anabolic steroids for physique goals and a man stopping prescribed TRT can arrive at the same endpoint. Both may have low LH, low FSH, and low testosterone for months or longer after discontinuation.

This is still secondary hypogonadism, not primary testicular failure, unless later testing shows high LH that suggests the testes can no longer respond. Some former anabolic steroid users continue to have lower testosterone levels and more hypogonadal symptoms years after cessation than controls.^[5] In this setting, Enclomiphene is increasingly used as a recovery tool because it restarts the suppressed HPG axis rather than extending suppression with more exogenous testosterone.^[14]

Other medications that lower testosterone

Several common medications in this group affect androgen action or reproductive hormones by reducing androgen signaling, raising prolactin, blocking steroid synthesis, or directly damaging the testes. Some lower testosterone directly, while others can cause sexual symptoms without necessarily causing biochemical testosterone deficiency.^{[1] [7] [8]}

Finasteride and dutasteride

Finasteride and dutasteride block 5 alpha reductase, the enzyme that converts testosterone to dihydrotestosterone, or DHT. DHT is the more potent androgen in some tissues, especially the prostate, skin, and hair follicles. Many young men take finasteride for hair loss without realizing that it can change androgen signaling even when total testosterone is unchanged or only mildly altered.

The immediate clinical problem is not always a severely low total testosterone value. It is reduced androgen effect, often with sexual side effects such as lower libido, erectile dysfunction, and altered sexual sensation. Persistent sexual side effects after finasteride have been reported in some men, although the broader post finasteride syndrome debate remains unsettled.^[6] The practical message is straightforward. Symptoms deserve a full workup, not dismissal, and that workup still needs morning testosterone, free testosterone, LH, and FSH.

SSRIs, glucocorticoids, and prolactin raising drugs

SSRIs and other antidepressants can contribute to sexual dysfunction and may also be part of the medication history in men presenting with low testosterone symptoms. Glucocorticoids can act through both central and testicular pathways, which means they can produce secondary suppression, primary damage, or a mixed picture depending on dose, duration, and the patient’s underlying illness.^[1]

Hyperprolactinemia inducing drugs deserve special attention. Prolactin is a pituitary hormone that suppresses GnRH when it is elevated in men. Medications that raise prolactin can cause secondary hypogonadism through reduced pituitary signaling.^[7] This is why prolactin should be checked when testosterone is low and LH is low or normal, or when low sexual desire is a major complaint.

Estrogens and progestogens also suppress the HPG axis. If the brain sees enough estrogenic or progestogenic feedback, LH and FSH fall and natural testosterone production falls with them. This is another setting where low or normal LH with low testosterone points to secondary suppression rather than primary failure.

Chemotherapy and steroid synthesis blockers

Chemotherapy agents, especially alkylating agents, are a classic cause of primary hypogonadism because they can damage testicular tissue directly.^[8] When the testes are damaged, LH often rises because the pituitary is trying harder to stimulate them. That high LH plus low testosterone pattern is why Enclomiphene is not appropriate in chemotherapy related primary hypogonadism. Damaged testes cannot be “woken up” if they can no longer respond.

Ketoconazole and aminoglutethimide lower testosterone by inhibiting steroid synthesis. Their effect is biochemical rather than behavioral. If a man develops symptoms while taking one of these drugs, the correct response is not to assume idiopathic low testosterone. It is to recognize a specific medication exposure and classify the lab pattern correctly.

Obesity, metabolic syndrome, and type 2 diabetes

Obesity is the single most evidence backed modifiable cause of low testosterone in men, and it usually produces functional secondary hypogonadism rather than irreversible testicular failure.^{[2] [9] [10]}

The link between obesity and testosterone is bidirectional. Aromatase is the enzyme in adipose tissue that converts testosterone to estradiol. As body fat rises, aromatase activity rises. Estradiol then increases negative feedback on the HPG axis, LH falls, testosterone falls, and visceral fat accumulation accelerates. This is a self reinforcing cycle, not a cosmetic issue.^{[2] [9]}

The European Male Ageing Study found that obesity was strongly linked to secondary hypogonadism, which is exactly the pattern clinicians see every day.^[2] That matters because obesity and testosterone problems are often reversible in principle but not always easy to reverse in practice. A 2013 meta analysis found that weight loss can improve obesity associated hypogonadism, but the gains are usually modest and long term maintenance is hard.^[9] At Veedma, that is why Enclomiphene plus lifestyle modification is the preferred first line approach for functional hypogonadism when LH is below 8 mIU/mL. It boosts natural production without shutting the axis down.

Metabolic syndrome adds another layer. Central obesity, hyperglycemia, insulin resistance, dyslipidemia, and hypertension cluster together, and each pushes testosterone lower. Hypogonadotropic hypogonadism is common in men with type 2 diabetes.^[10] Insulin resistance also appears to impair testicular function independently, which means these men can have both central and peripheral pressure on testosterone production.

Erectile dysfunction is extremely common in men with metabolic syndrome or type 2 diabetes, reaching roughly 70% in some series, and low testosterone is often one component of that picture. When obesity and testosterone fall together, the correct label is often functional hypogonadism. That means the axis is suppressed, not destroyed, and treatment should reflect that. If you want the lab roadmap for sorting this out, see the complete testing guide.

Alcohol, environmental toxins, and chronic disease

Alcohol, endocrine disrupting chemicals, and chronic systemic illness can lower testosterone through mixed mechanisms that involve both central suppression and impaired testicular function.^{[11] [12]}

Alcohol and testosterone

Chronic heavy alcohol use is not just a liver issue. It has direct toxic effects on the testes and also changes hepatic hormone handling, which can alter SHBG and testosterone bioavailability. Chronic heavy alcohol use has been associated with impaired reproductive hormones and poorer semen quality in men.^[11] Clinically, alcohol can produce a mixed picture with both primary damage and secondary HPG suppression.

That mixed mechanism is why labs matter. A man with chronic heavy alcohol exposure may show high LH if testicular injury dominates, or low or normal LH if central suppression dominates. The treatment path is not the same in those two scenarios.

Environmental toxins

Environmental endocrine disrupting chemicals such as BPA, phthalates, PFAS, and some pesticides have antiandrogenic effects and are plausible contributors to lower testosterone across the male lifespan.^[12]

According to the Endocrine Society’s scientific statement, these exposures are widespread and can interfere with hormone signaling, with special concern during fetal development and puberty when male reproductive development is most vulnerable.^[12]

Chronic disease and acute illness

Chronic systemic diseases can act at both levels of the axis and produce mixed hypogonadism.^{[1] [2]} That includes chronic organ failure, Cushing syndrome, HIV, COPD, renal disease, and cancer. In these settings, inflammation, malnutrition, organ dysfunction, and medication burden all converge. The testes may function less well, while hypothalamic and pituitary signaling also weakens.

Acute and critical illness are different. They can temporarily suppress testosterone enough to mimic hypogonadism, but this may be transient functional suppression rather than a chronic disorder. According to the Endocrine Society guideline, testosterone should not be diagnosed during acute illness because the result may normalize after recovery.^[1] If a low value was drawn during hospitalization, infection, surgery, or another acute stressor, repeat testing after recovery is mandatory.

Lifestyle causes of low testosterone

The most important lifestyle causes of low testosterone are chronic sleep deprivation, endurance overtraining, eating disorders, and persistent stress, all of which can suppress the HPG axis without permanently damaging the testes.^{[13] [1]}

Sleep deprivation

Testosterone production is tightly linked to sleep. Just one week of sleep restriction in healthy young men has been shown to reduce daytime testosterone levels by 10% to 15%.^[13] For men with chronic short sleep, rotating shift work, untreated sleep disruption, or repeated late night wakefulness, the endocrine effect can be clinically meaningful. This is one of the most overlooked lifestyle causes of low testosterone.

Chronic stress

Chronic stress raises cortisol, and cortisol suppresses hypothalamic GnRH output. Cortisol is the body’s main stress hormone. If cortisol stays high long enough, LH stimulation to the testes falls and testosterone follows. This is usually secondary hypogonadism, which means the suppression may improve when the stressor is treated, sleep normalizes, and other metabolic strain is reduced.^[1]

Endurance overtraining and eating disorders

According to major clinical guidance, endurance overtraining and eating disorders are recognized causes of acquired secondary hypogonadism.^[1] The common pathway is low energy availability. When calorie intake is chronically inadequate for training load or basic physiologic needs, the brain down regulates reproductive signaling. In plain language, the body stops prioritizing testosterone production when it perceives sustained metabolic threat.

These factors are especially important to identify because they are often reversible. When the testes are intact and LH remains low or normal, Enclomiphene can be a useful bridge while the underlying sleep, nutrition, stress, or training problem is being corrected. If those drivers are ignored, men can be mislabeled as having irreversible low testosterone when the real problem is suppressive lifestyle exposure.

Myth vs fact

Myth: A single low testosterone result proves you have hypogonadism

Fact: Male hypogonadism requires persistent symptoms plus confirmed biochemical deficiency on repeat morning testing. Acute illness, poor sleep, stress, and recent substance exposure can all transiently lower testosterone, which is why guidelines warn against diagnosing it from a single untimed result.^[1]

Myth: Taking testosterone cannot cause low testosterone

Fact: Exogenous testosterone and anabolic steroids suppress LH and FSH through negative feedback, which can leave natural testosterone production shut down after use stops. Some former users remain symptomatic for months or longer, and some have persistent hypogonadal symptoms years later.^{[4] [5]}

Myth: Hair loss drugs do not affect male hormones

Fact: Finasteride and dutasteride alter androgen metabolism by blocking conversion of testosterone to DHT, without necessarily lowering testosterone itself. Sexual side effects are well documented, and persistent symptoms after discontinuation remain an active clinical controversy that should not be dismissed without a proper hormonal workup.^[6]

Myth: Obesity related low testosterone is just about weight

Fact: The relationship between obesity and testosterone is endocrine, metabolic, and self reinforcing. Excess fat raises aromatase activity, increases estradiol, suppresses LH, and promotes more visceral adiposity. Men with type 2 diabetes commonly have secondary hypogonadism as part of this loop.^{[9] [10]}

Myth: Lifestyle change alone reliably fixes functional hypogonadism

Fact: Weight loss, sleep recovery, and removal of offending drugs can improve testosterone, but the average rise is often modest and long term relapse is common. That is why Veedma uses Enclomiphene as first line therapy for secondary and functional hypogonadism when LH is below 8 mIU/mL, especially when the axis is suppressed but still intact.^{[9] [14]}

Bottom line

Yes. Many medications and lifestyle factors such as opioids, exogenous androgens, obesity, alcohol, sleep loss, and chronic stress can quietly push men into clinically significant hypogonadism, while finasteride can alter androgen effect and cause sexual symptoms even when testosterone is not frankly low. The key next step is not guessing. It is confirming persistent symptoms, measuring total and free testosterone in the morning, and always checking LH and FSH so the problem is classified correctly before treatment. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018;103:1715-1744. PMID: 29562364
2. Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. The Journal of clinical endocrinology and metabolism. 2010;95:1810-1818. PMID: 20173018
3. Vuong C, Van Uum SHM, O’Dell LE, et al. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocrine reviews. 2010;31:98-132. PMID: 19887568
4. Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. The Journal of clinical endocrinology and metabolism. 2005;90:2595-2602. PMID: 15713727
5. Rasmussen JJ, Selmer C, Østergren PB, et al. Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study. PloS one. 2016;11:e0161208. PMID: 27564846
6. Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? The journal of sexual medicine. 2012;9:2927-32. PMID: 22789024
7. Molitch ME. Drugs and prolactin. Pituitary. 2008;11:209-218. PMID: 18465287
8. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. Journal of the National Cancer Institute. Monographs. 2005:12-17. PMID: 15784814
9. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European journal of endocrinology. 2013;168:829-843. PMID: 23482592
10. Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2004;89:5462-5468. PMID: 15531491
11. Sansone A, Di Dato C, de Angelis C, et al. Smoke, alcohol and drug addiction and male fertility. Reproductive biology and endocrinology. 2018;16:3. PMID: 29334961
12. Gore AC, Chappell VA, Fenton SE, et al. EDC-2: The Endocrine Society’s Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocrine reviews. 2015;36:E1-E150. PMID: 26544531
13. Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA. 2011;305:2173-2174. PMID: 21632415
14. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertility and sterility. 2014;102:720-727. PMID: 24593086